Given the role of CLC3 in promoting chemoresistance, lysosomal function, and tumor stemness, targeting CLC3 or its downstream effectors, such as V-ATPase—especially ATP6V1A—may represent a promising therapeutic strategy. This evidence concerns the gene CLCN3 and neoplasm.